Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Risk Factor Analysis and Molecular Epidemiological Investigation of Carbapenem-Resistant (CRE) Infection in Patients with Acute Pancreatitis.
Infect Drug Resist
January 2025
Department of Clinical Laboratory, Chongqing Red Cross Hospital (Jiangbei District People's Hospital), Chongqing, People's Republic of China.
Objective: Patients with acute pancreatitis (AP) complicated by carbapenem-resistant (CRE) infection often have a higher mortality rate. However, little investigation on the risk factor analysis has been published for the AP complicated by CRE. Therefore, this study conducted a retrospective analysis of the clinical characteristics, risk factors, and molecular epidemiological features associated with CRE infection in patients with AP.
View Article and Find Full Text PDFLactic acid/tartaric acid-maltitol antibacterial activity against spoilage bacteria and prevention of yellowing and wilting in spinach and oilseed rape.
Food Chem
December 2024
College of Food Science and Engineering, Jilin Agricultural University, Changchun 130118, Jilin, China. Electronic address:
The wilting and yellowing of leafy vegetables caused by spoilage bacteria resulted in serious resource wastage. This study investigated the efficacy of a combined lactic acid (LA) and tartaric acid (TA) treatment against four predominant spoilage bacteria (Erwinia persicina, Citrobacter freundii, Pseudomonas putida, and Pseudomonas punonensis) isolated from spinach and oilseed rape. Detailed analysis using Fourier-transform infrared spectroscopy, flow cytometry, scanning electron microscopy, and light microscopy revealed substantial cellular damage in the bacteria treated by LA and TA, including loss of intracellular material, and collapse of cellular morphology, as well as effective biofilm removal.
View Article and Find Full Text PDFPredictive Application Value of Metagenomic Next-Generation Sequencing in the Resistance of Carbapenem-Resistant Enterobacteriaceae.
Can J Infect Dis Med Microbiol
January 2025
Department of Clinical Laboratory, Liaocheng People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Although metagenomic next-generation sequencing (mNGS) technology has achieved notable outcomes in pathogen detection, there remains a gap in the research regarding its application in predicting the antibiotic resistance of pathogenic bacteria. This study aims to analyze the clinical application value of mNGS in predicting the resistance of carbapenem-resistant Enterobacteriaceae (CRE), as well as the relevant influencing factors, thereby providing valuable insights for clinical antimicrobial therapy. Nonduplicate isolates of bacteria collected from Liaocheng People's Hospital from April 2023 to June 2024 were selected, and CRE bacteria were screened.
View Article and Find Full Text PDFDiversification of -harbouring plasmids among carbapenemase-producing , 11 years after a large outbreak in a general hospital in the Netherlands.
Microb Genom
January 2025
Center for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands.
Genes encoding OXA-48-like carbapenem-hydrolyzing enzymes are often located on plasmids and are abundant among carbapenemase-producing (CPE) worldwide. After a large plasmid-mediated outbreak in 2011, routine screening of patients at risk of CPE carriage on admission and every 7 days during hospitalization was implemented in a large hospital in the Netherlands. The objective of this study was to investigate the dynamics of the hospitals' 2011 outbreak-associated plasmid among CPE collected from 2011 to 2021.
View Article and Find Full Text PDFNational Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for .
Antibiotics (Basel)
December 2024
Microbiology Laboratory, Bicêtre University Hospital, AP-HP Paris Saclay University, 94270 Le Kremlin-Bicêtre, France.
Background: Meropenem-vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an effective inhibitor of KPC enzymes in vitro. This study aimed to describe the initial uses and efficacy of MEM-VAB for compassionate treatment during the first 21 months following its early access in France.
Method: A national multicenter retrospective study was conducted, including all patients who received at least one dose of MEM-VAB between 20 July 2020, and 5 April 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!